Jump to content

Schrödinger, Inc.: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m v2.04b - Bot T20 CW#61 - Fix errors for CW project (Reference before punctuation)
→Partners: improved ref
Line 36: Line 36:


==Partners==
==Partners==
Schrödinger's partners include larger pharmaceutical companies, including [[Bayer]]<ref>{{Cite press release|url=https://ir.schrodinger.com/news-releases/news-release-details/schrodinger-and-bayer-collaborate-co-develop-de-novo-design}}</ref>,[[Takeda Pharmaceutical Company|Takeda]],<ref>{{Cite press release|url=https://www.fiercebiotech.com/cro/takeda-schrodinger-form-multiprogram-drug-discovery-pact|title=Takeda, Schrödinger form multiprogram drug discovery pact|last=Liu|first=Angus|date=July 20, 2017|website=FierceBiotech}}</ref> [[Sanofi]].<ref>{{Cite press release|url=https://www.fiercebiotech.com/partnering/sanofi-adds-a-120m-computational-drug-design-deal-schr%C3%B6dinger|title=Partnering Sanofi adds a $120M computational drug design deal with Schrödinger|last=Carroll|first=John|date=April 2, 2015|website=FierceBiotech}}</ref>, and [[Bristol Myers Squibb]]<ref>{{Cite press release|url=https://ir.schrodinger.com/news-releases/news-release-details/schrodinger-announces-multi-target-drug-discovery-development|title=Schrödinger Announces a Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers Squibb|date=November 23, 2020 | website=Schrodinger}}</ref>
Schrödinger's partners include larger pharmaceutical companies, including [[Bayer]]<ref>{{Cite press release|url=https://ir.schrodinger.com/news-releases/news-release-details/schrodinger-and-bayer-collaborate-co-develop-de-novo-design|title=Schrödinger and Bayer Collaborate to Co-Develop de novo Design Technology to Accelerate Drug Discovery|date=8 January 2020|website=Schrödinger|access-date=12 March 2021}}</ref>,[[Takeda Pharmaceutical Company|Takeda]],<ref>{{Cite press release|url=https://www.fiercebiotech.com/cro/takeda-schrodinger-form-multiprogram-drug-discovery-pact|title=Takeda, Schrödinger form multiprogram drug discovery pact|last=Liu|first=Angus|date=July 20, 2017|website=FierceBiotech}}</ref> [[Sanofi]].<ref>{{Cite press release|url=https://www.fiercebiotech.com/partnering/sanofi-adds-a-120m-computational-drug-design-deal-schr%C3%B6dinger|title=Partnering Sanofi adds a $120M computational drug design deal with Schrödinger|last=Carroll|first=John|date=April 2, 2015|website=FierceBiotech}}</ref>, and [[Bristol Myers Squibb]]<ref>{{Cite press release|url=https://ir.schrodinger.com/news-releases/news-release-details/schrodinger-announces-multi-target-drug-discovery-development|title=Schrödinger Announces a Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers Squibb|date=November 23, 2020 | website=Schrodinger}}</ref>


Nimbus Therapeutics, co-founded by Schrödinger, uses Schrödinger's drug screening and design platform for drug discovery. In 2016, Nimbus Therapeutics sold an [[Acetyl-CoA carboxylase]] (ACC) inhibitor designed by Schrödinger to Gilead in a deal worth up to $1.2 billion.<ref>{{Cite press release|last1=Flood|first1=Amy|last2=O’Brien|first2=Patrick|last3=Melone|first3=Liz|url=https://www.businesswire.com/news/home/20160404005324/en/Gilead-Sciences-Announces-Acquisition-Nimbus-Therapeutics%E2%80%99-Acetyl-CoA|title=Gilead Sciences Announces Acquisition of Nimbus Therapeutics' Acetyl-CoA Carboxlyase (ACC) Program for NASH and Other Liver Diseases|date=2016-04-04|website=www.businesswire.com|language=en|access-date=2019-06-19}}</ref> As of spring 2019 the ACC inhibitor was moving through late-stage clinical trials in NASH.<ref>{{Cite press release|url=https://www.gilead.com/news-and-press/press-room/press-releases/2019/4/gilead-announces-topline-data-from-phase-3-stellar3-study-of-selonsertib-in-bridging-fibrosis-f3-due-to-nonalcoholic-steatohepatitis-nash|title=Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)|website=www.gilead.com|access-date=2019-06-19}}</ref>
Nimbus Therapeutics, co-founded by Schrödinger, uses Schrödinger's drug screening and design platform for drug discovery. In 2016, Nimbus Therapeutics sold an [[Acetyl-CoA carboxylase]] (ACC) inhibitor designed by Schrödinger to Gilead in a deal worth up to $1.2 billion.<ref>{{Cite press release|last1=Flood|first1=Amy|last2=O’Brien|first2=Patrick|last3=Melone|first3=Liz|url=https://www.businesswire.com/news/home/20160404005324/en/Gilead-Sciences-Announces-Acquisition-Nimbus-Therapeutics%E2%80%99-Acetyl-CoA|title=Gilead Sciences Announces Acquisition of Nimbus Therapeutics' Acetyl-CoA Carboxlyase (ACC) Program for NASH and Other Liver Diseases|date=2016-04-04|website=www.businesswire.com|language=en|access-date=2019-06-19}}</ref> As of spring 2019 the ACC inhibitor was moving through late-stage clinical trials in NASH.<ref>{{Cite press release|url=https://www.gilead.com/news-and-press/press-room/press-releases/2019/4/gilead-announces-topline-data-from-phase-3-stellar3-study-of-selonsertib-in-bridging-fibrosis-f3-due-to-nonalcoholic-steatohepatitis-nash|title=Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)|website=www.gilead.com|access-date=2019-06-19}}</ref>

Revision as of 05:54, 21 March 2021

Schrödinger
Company typePublic
Nasdaq: SDGR
Russell 2000 Index component
Industry
Founded1990
FounderRichard A. Friesner,
William A. Goddard III
HeadquartersNew York, NY
Area served
Worldwide
Key people
Ramy Farid
(President & CEO)
Michael Lynton
(Chairman)
Products
  • Advanced computational platform for drug discovery and materials science
  • LiveDesign
  • PyMOL
RevenueIncrease $85.4 Million(2019)[1]
Number of employees
450
Websiteschrodinger.com

Schrödinger, Inc. is an American life sciences and materials science company founded in 1990 that develops software for computational chemistry and has a pipeline of collaborative and internal drug discovery programs. The company is headquartered in New York, with regional headquarters in Munich, Tokyo and Bangalore.

Products

Schrödinger's computational platforms evaluate compounds in silico, with experimental accuracy on properties such as binding affinity and solubility. Schrödinger's products include molecular modeling programs, and an Enterprise Informatics Platform named LiveDesign, an enterprise application designed to facilitate communication among interdisciplinary research teams.[2]

Services

In addition to its computational platforms Schrödinger provides professional services, including custom software development and training, computer-cluster design and implementation, and research-based drug discovery projects.[3][4]

Partners

Schrödinger's partners include larger pharmaceutical companies, including Bayer[5],Takeda,[6] Sanofi.[7], and Bristol Myers Squibb[8]

Nimbus Therapeutics, co-founded by Schrödinger, uses Schrödinger's drug screening and design platform for drug discovery. In 2016, Nimbus Therapeutics sold an Acetyl-CoA carboxylase (ACC) inhibitor designed by Schrödinger to Gilead in a deal worth up to $1.2 billion.[9] As of spring 2019 the ACC inhibitor was moving through late-stage clinical trials in NASH.[10]

Recognition

In November 2013, Schrödinger, in collaboration with Cycle Computing and the University of Southern California, set a record for the world's largest and fastest cloud computing run by using 156,000 cores on Amazon Web Services to screen over 205,000 molecules for materials science research.[11] That work was a follow up to a 2012 collaboration which saw Cycle Computing creating a 50,000 core virtual supercomputer using Amazon infrastructure and Schrödinger's Glide program, which at that time was used to analyze 2.1 million compounds in 3 hours.[12]

See also

References

  1. ^ https://www.macrotrends.net/stocks/charts/SDGR/schrodinger/revenue
  2. ^ "LiveDesign". LiveDesign.
  3. ^ Booth, Bruce (June 27, 2013). "The Nimbus Experiment: Structure-Based Drug Deals". Forbes.
  4. ^ "Schrodinger and Professor Mark E. Thompson (USC) Announce Research Collaboration to Enable Computer'Aided Design of Organic Semiconductor Materials" (Press release). June 2013. Retrieved 20 October 2014.
  5. ^ "Schrödinger and Bayer Collaborate to Co-Develop de novo Design Technology to Accelerate Drug Discovery". Schrödinger (Press release). 8 January 2020. Retrieved 12 March 2021.
  6. ^ Liu, Angus (July 20, 2017). "Takeda, Schrödinger form multiprogram drug discovery pact". FierceBiotech (Press release).
  7. ^ Carroll, John (April 2, 2015). "Partnering Sanofi adds a $120M computational drug design deal with Schrödinger". FierceBiotech (Press release).
  8. ^ "Schrödinger Announces a Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers Squibb". Schrodinger (Press release). November 23, 2020.
  9. ^ Flood, Amy; O’Brien, Patrick; Melone, Liz (2016-04-04). "Gilead Sciences Announces Acquisition of Nimbus Therapeutics' Acetyl-CoA Carboxlyase (ACC) Program for NASH and Other Liver Diseases". www.businesswire.com (Press release). Retrieved 2019-06-19.
  10. ^ "Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)". www.gilead.com (Press release). Retrieved 2019-06-19.
  11. ^ Shankland, Stephen (November 12, 2013). "Supercomputing simulation employs 156,000 Amazon processor cores". CNet.
  12. ^ Brodkin, Jon (April 19, 2012). "$4,829-per-hour supercomputer built on Amazon cloud to fuel cancer research". Ars Technica.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Schrödinger,_Inc.&oldid=1013361418"